Review



binding to tim3  (ACROBiosystems)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    ACROBiosystems binding to tim3
    Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of <t>TIM3</t> (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).
    Binding To Tim3, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/binding to tim3/product/ACROBiosystems
    Average 94 stars, based on 6 article reviews
    binding to tim3 - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies"

    Article Title: AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2025.1499810

    Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of TIM3 (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).
    Figure Legend Snippet: Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of TIM3 (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).

    Techniques Used: Binding Assay, Produced, Recombinant, Incubation, Software, Transfection, Expressing, Cell Culture, Control, Isolation, Staining

    Binding constants.
    Figure Legend Snippet: Binding constants.

    Techniques Used: Binding Assay

    Post-translation modifications analysis. (A) PTM motifs shown on VH-VL 3D representations. The main PTM-prone residues of the identified deamidation, isomerization, and methionine or tryptophan oxidation sites are shown in colored spheres. The antibodies surfaces are shown in grey (frameworks) and pale green (CDRs). (B, C) Comparison with INN antibodies. The number of PTM motifs with solvent accessibility higher than 30% were computed from 735 INN antibodies. The number of motifs identified for our anti-TIGIT (B) and anti-TIM3 (C) candidates and their references are shown as colored lines are compared with the distribution of the INN antibodies shown in blue.
    Figure Legend Snippet: Post-translation modifications analysis. (A) PTM motifs shown on VH-VL 3D representations. The main PTM-prone residues of the identified deamidation, isomerization, and methionine or tryptophan oxidation sites are shown in colored spheres. The antibodies surfaces are shown in grey (frameworks) and pale green (CDRs). (B, C) Comparison with INN antibodies. The number of PTM motifs with solvent accessibility higher than 30% were computed from 735 INN antibodies. The number of motifs identified for our anti-TIGIT (B) and anti-TIM3 (C) candidates and their references are shown as colored lines are compared with the distribution of the INN antibodies shown in blue.

    Techniques Used: Comparison, Solvent

    Aggregation parameters analysis. (A) Surface physicochemical patches. Surface properties (i.e. hydrophobicity, electrostatic forces, charges and shape) of the VH-VL pairs were computed and moderate (orange) to intense (red) regions were shown on the VH-VL structures. (B, C) Aggregation scores comparison with publicly-disclosed antibodies. The surface properties were used to train a model allowing to predict an aggregation score. Scores were computed for our anti-TIGIT (B) and anti-TIM3 (C) candidates and their references, and compared with the scores distribution computed from 735 INN antibodies (blue) and 31,712 patented antibodies (green).
    Figure Legend Snippet: Aggregation parameters analysis. (A) Surface physicochemical patches. Surface properties (i.e. hydrophobicity, electrostatic forces, charges and shape) of the VH-VL pairs were computed and moderate (orange) to intense (red) regions were shown on the VH-VL structures. (B, C) Aggregation scores comparison with publicly-disclosed antibodies. The surface properties were used to train a model allowing to predict an aggregation score. Scores were computed for our anti-TIGIT (B) and anti-TIM3 (C) candidates and their references, and compared with the scores distribution computed from 735 INN antibodies (blue) and 31,712 patented antibodies (green).

    Techniques Used: Comparison

    Humanness evaluation. A humanness score was computed from publicly available antibody sequences which allowed discrimination between human, humanized and non-human sequences (from chimeric antibodies). Separate scores were computed for the VH (A, C) and the VL (B, D) . The scores obtained for our anti-TIGIT (upper panels) and anti-TIM3 (lower panels) candidates are compared with the benchmark distributions.
    Figure Legend Snippet: Humanness evaluation. A humanness score was computed from publicly available antibody sequences which allowed discrimination between human, humanized and non-human sequences (from chimeric antibodies). Separate scores were computed for the VH (A, C) and the VL (B, D) . The scores obtained for our anti-TIGIT (upper panels) and anti-TIM3 (lower panels) candidates are compared with the benchmark distributions.

    Techniques Used:

    Off-targets prediction. The numbers of predicted off-targets, either human (red) or non-human (blue), were computed for all FDA-approved antibodies and ranked as a probability of being recognized (high vs. medium). The number of off-targets predicted for our anti-TIGIT (left panel) and anti-TIM3 (right panel) candidates were compared with that scale.
    Figure Legend Snippet: Off-targets prediction. The numbers of predicted off-targets, either human (red) or non-human (blue), were computed for all FDA-approved antibodies and ranked as a probability of being recognized (high vs. medium). The number of off-targets predicted for our anti-TIGIT (left panel) and anti-TIM3 (right panel) candidates were compared with that scale.

    Techniques Used:

    Affinity evaluation and structural model definition of the antibody-antigen complexes. (A, B) Experimental competition assays. Pairwise competition assays of TIGIT binders (A) or anti-TIM3 antibodies (B) were performed by flow cytometry. Briefly, the Fc fragments of our human IgG1 candidates were replaced by mouse IgG2a Fc fragments. HEK293 cells were transiently transfected with the Flag-tagged target gene and co-incubated the human IgG1-formatted and the mouse IgG2a-formatted candidates. In the case of TIGIT, the competition was also evaluated with its natural ligand CD155 fused to a mouse IgG2a Fc fragment. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the human IgG1-formatted antibodies was followed with an APC-coupled antibody. The percentage of APC+PE+ cells (among the PE+ subset) was indicated as a color gradient. (C) Affinity predictions and structural model definition. The antibodies were docked on selected epitopes (indicated in the left boxes). The affinity of the obtained complexes was computed as the C-score (left column) which was a combination of PCC-score (middle column) and IR-score (right column). The upper panels show the affinity predicted for the anti-TIGIT candidates docked on 7VYT epitope. The middle and lower panels show the affinity predicted for the anti-TIM3 antibodies docked on 6TXZ and 7KQL epitope, respectively.
    Figure Legend Snippet: Affinity evaluation and structural model definition of the antibody-antigen complexes. (A, B) Experimental competition assays. Pairwise competition assays of TIGIT binders (A) or anti-TIM3 antibodies (B) were performed by flow cytometry. Briefly, the Fc fragments of our human IgG1 candidates were replaced by mouse IgG2a Fc fragments. HEK293 cells were transiently transfected with the Flag-tagged target gene and co-incubated the human IgG1-formatted and the mouse IgG2a-formatted candidates. In the case of TIGIT, the competition was also evaluated with its natural ligand CD155 fused to a mouse IgG2a Fc fragment. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the human IgG1-formatted antibodies was followed with an APC-coupled antibody. The percentage of APC+PE+ cells (among the PE+ subset) was indicated as a color gradient. (C) Affinity predictions and structural model definition. The antibodies were docked on selected epitopes (indicated in the left boxes). The affinity of the obtained complexes was computed as the C-score (left column) which was a combination of PCC-score (middle column) and IR-score (right column). The upper panels show the affinity predicted for the anti-TIGIT candidates docked on 7VYT epitope. The middle and lower panels show the affinity predicted for the anti-TIM3 antibodies docked on 6TXZ and 7KQL epitope, respectively.

    Techniques Used: Flow Cytometry, Transfection, Incubation, Expressing, Binding Assay



    Similar Products

    tim3 binding to galectin-9  (Galectin Therapeutics)
    90
    Galectin Therapeutics tim3 binding to galectin-9
    Tim3 Binding To Galectin 9, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3 binding to galectin-9/product/Galectin Therapeutics
    Average 90 stars, based on 1 article reviews
    tim3 binding to galectin-9 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    tim3 binding by galectin-9  (Galectin Therapeutics)
    90
    Galectin Therapeutics tim3 binding by galectin-9
    Tim3 Binding By Galectin 9, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3 binding by galectin-9/product/Galectin Therapeutics
    Average 90 stars, based on 1 article reviews
    tim3 binding by galectin-9 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    binding to tim3  (ACROBiosystems)
    94
    ACROBiosystems binding to tim3
    Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of <t>TIM3</t> (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).
    Binding To Tim3, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/binding to tim3/product/ACROBiosystems
    Average 94 stars, based on 1 article reviews
    binding to tim3 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    fully human antibodies that bind tim3  (Sorrento Therapeutics)
    90
    Sorrento Therapeutics fully human antibodies that bind tim3
    Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of <t>TIM3</t> (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).
    Fully Human Antibodies That Bind Tim3, supplied by Sorrento Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fully human antibodies that bind tim3/product/Sorrento Therapeutics
    Average 90 stars, based on 1 article reviews
    fully human antibodies that bind tim3 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    tim3−gal9 binding  (Galectin Therapeutics)
    90
    Galectin Therapeutics tim3−gal9 binding
    Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of <t>TIM3</t> (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).
    Tim3−Gal9 Binding, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3−gal9 binding/product/Galectin Therapeutics
    Average 90 stars, based on 1 article reviews
    tim3−gal9 binding - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    tim3−galectin 9 binding pathways  (Galectin Therapeutics)
    90
    Galectin Therapeutics tim3−galectin 9 binding pathways
    Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of <t>TIM3</t> (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).
    Tim3−Galectin 9 Binding Pathways, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3−galectin 9 binding pathways/product/Galectin Therapeutics
    Average 90 stars, based on 1 article reviews
    tim3−galectin 9 binding pathways - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    antigen binding properties of multispecific antibodies which bind to pd1 and tim3  (Biacore)
    90
    Biacore antigen binding properties of multispecific antibodies which bind to pd1 and tim3
    Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of <t>TIM3</t> (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).
    Antigen Binding Properties Of Multispecific Antibodies Which Bind To Pd1 And Tim3, supplied by Biacore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antigen binding properties of multispecific antibodies which bind to pd1 and tim3/product/Biacore
    Average 90 stars, based on 1 article reviews
    antigen binding properties of multispecific antibodies which bind to pd1 and tim3 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    tim3 binding partner galectin-9  (Galectin Therapeutics)
    90
    Galectin Therapeutics tim3 binding partner galectin-9
    Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of <t>TIM3</t> (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).
    Tim3 Binding Partner Galectin 9, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3 binding partner galectin-9/product/Galectin Therapeutics
    Average 90 stars, based on 1 article reviews
    tim3 binding partner galectin-9 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    antigen binding properties of multispecific antibodies which bind to pd land tim3  (Biacore)
    90
    Biacore antigen binding properties of multispecific antibodies which bind to pd land tim3
    Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of <t>TIM3</t> (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).
    Antigen Binding Properties Of Multispecific Antibodies Which Bind To Pd Land Tim3, supplied by Biacore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antigen binding properties of multispecific antibodies which bind to pd land tim3/product/Biacore
    Average 90 stars, based on 1 article reviews
    antigen binding properties of multispecific antibodies which bind to pd land tim3 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of TIM3 (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).

    Journal: Frontiers in Immunology

    Article Title: AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies

    doi: 10.3389/fimmu.2025.1499810

    Figure Lengend Snippet: Binding validation and specificity assessment of the 5 final candidates. The 5 final candidates and the reference antibodies were produced as human IgG1 in HEK293 supernatant, concentrated and dosed. (A, B) : Binding validation. For HTRF assays, the recombinant extracellular domains of TIM3 (A) or TIGIT (B) fused to a biotinylated Avitag were incubated with increasing concentrations of the antibodies. Antibodies and targets were detected with fluorophore-coupled sensors: d2 acceptor coupled to an anti-IgG and terbium donor coupled to the streptavidin. The binding was assessed as the energy transfer between the donor and acceptor and computed as the HTRF ratio: 665nm acceptor emission/620 nm donor emission x 10,000. Curves were fitted mathematically with GraphPad Prism software. (C) Specificity evaluation of the candidates. HEK293 cells were transiently transfected with the Flag-tagged target gene and incubated with the candidate or reference antibodies. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the antibodies was followed with an APC-coupled anti-IgG. Percentage of APC+ PE+ cells among the total PE+ cell population was indicated through a color gradient. (D–F) Binding of endogenous TIM3 by 6E9 in immune-relevant cells. NK lines NKL and NK-92 (D) , activated PBMC (E) and TRM cultured with TGF-β1 and IL-15 (F) were incubated with 6E9 or 7KQL as a control. The T and NK lymphocytes subsets of the PBMC and TRM were optically isolated after staining of CD3 and CD56 (CD3+ T lymphocytes and CD3-CD56+ NK lymphocytes).

    Article Snippet: Antibodies-containing HEK293 supernatants were diluted in PPI Terbium Detection buffer and the binding to TIM3 (6-His C-ter-tagged, Acro Biosystems) or TIGIT (TIT-H52H5 Human TIGIT Protein, His Tag, active dimer, AcroBiosystems) diluted at 0.6 ng/µl final concentration in small volume 384-wells plates (Greiner Bio-One).

    Techniques: Binding Assay, Produced, Recombinant, Incubation, Software, Transfection, Expressing, Cell Culture, Control, Isolation, Staining

    Binding constants.

    Journal: Frontiers in Immunology

    Article Title: AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies

    doi: 10.3389/fimmu.2025.1499810

    Figure Lengend Snippet: Binding constants.

    Article Snippet: Antibodies-containing HEK293 supernatants were diluted in PPI Terbium Detection buffer and the binding to TIM3 (6-His C-ter-tagged, Acro Biosystems) or TIGIT (TIT-H52H5 Human TIGIT Protein, His Tag, active dimer, AcroBiosystems) diluted at 0.6 ng/µl final concentration in small volume 384-wells plates (Greiner Bio-One).

    Techniques: Binding Assay

    Post-translation modifications analysis. (A) PTM motifs shown on VH-VL 3D representations. The main PTM-prone residues of the identified deamidation, isomerization, and methionine or tryptophan oxidation sites are shown in colored spheres. The antibodies surfaces are shown in grey (frameworks) and pale green (CDRs). (B, C) Comparison with INN antibodies. The number of PTM motifs with solvent accessibility higher than 30% were computed from 735 INN antibodies. The number of motifs identified for our anti-TIGIT (B) and anti-TIM3 (C) candidates and their references are shown as colored lines are compared with the distribution of the INN antibodies shown in blue.

    Journal: Frontiers in Immunology

    Article Title: AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies

    doi: 10.3389/fimmu.2025.1499810

    Figure Lengend Snippet: Post-translation modifications analysis. (A) PTM motifs shown on VH-VL 3D representations. The main PTM-prone residues of the identified deamidation, isomerization, and methionine or tryptophan oxidation sites are shown in colored spheres. The antibodies surfaces are shown in grey (frameworks) and pale green (CDRs). (B, C) Comparison with INN antibodies. The number of PTM motifs with solvent accessibility higher than 30% were computed from 735 INN antibodies. The number of motifs identified for our anti-TIGIT (B) and anti-TIM3 (C) candidates and their references are shown as colored lines are compared with the distribution of the INN antibodies shown in blue.

    Article Snippet: Antibodies-containing HEK293 supernatants were diluted in PPI Terbium Detection buffer and the binding to TIM3 (6-His C-ter-tagged, Acro Biosystems) or TIGIT (TIT-H52H5 Human TIGIT Protein, His Tag, active dimer, AcroBiosystems) diluted at 0.6 ng/µl final concentration in small volume 384-wells plates (Greiner Bio-One).

    Techniques: Comparison, Solvent

    Aggregation parameters analysis. (A) Surface physicochemical patches. Surface properties (i.e. hydrophobicity, electrostatic forces, charges and shape) of the VH-VL pairs were computed and moderate (orange) to intense (red) regions were shown on the VH-VL structures. (B, C) Aggregation scores comparison with publicly-disclosed antibodies. The surface properties were used to train a model allowing to predict an aggregation score. Scores were computed for our anti-TIGIT (B) and anti-TIM3 (C) candidates and their references, and compared with the scores distribution computed from 735 INN antibodies (blue) and 31,712 patented antibodies (green).

    Journal: Frontiers in Immunology

    Article Title: AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies

    doi: 10.3389/fimmu.2025.1499810

    Figure Lengend Snippet: Aggregation parameters analysis. (A) Surface physicochemical patches. Surface properties (i.e. hydrophobicity, electrostatic forces, charges and shape) of the VH-VL pairs were computed and moderate (orange) to intense (red) regions were shown on the VH-VL structures. (B, C) Aggregation scores comparison with publicly-disclosed antibodies. The surface properties were used to train a model allowing to predict an aggregation score. Scores were computed for our anti-TIGIT (B) and anti-TIM3 (C) candidates and their references, and compared with the scores distribution computed from 735 INN antibodies (blue) and 31,712 patented antibodies (green).

    Article Snippet: Antibodies-containing HEK293 supernatants were diluted in PPI Terbium Detection buffer and the binding to TIM3 (6-His C-ter-tagged, Acro Biosystems) or TIGIT (TIT-H52H5 Human TIGIT Protein, His Tag, active dimer, AcroBiosystems) diluted at 0.6 ng/µl final concentration in small volume 384-wells plates (Greiner Bio-One).

    Techniques: Comparison

    Humanness evaluation. A humanness score was computed from publicly available antibody sequences which allowed discrimination between human, humanized and non-human sequences (from chimeric antibodies). Separate scores were computed for the VH (A, C) and the VL (B, D) . The scores obtained for our anti-TIGIT (upper panels) and anti-TIM3 (lower panels) candidates are compared with the benchmark distributions.

    Journal: Frontiers in Immunology

    Article Title: AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies

    doi: 10.3389/fimmu.2025.1499810

    Figure Lengend Snippet: Humanness evaluation. A humanness score was computed from publicly available antibody sequences which allowed discrimination between human, humanized and non-human sequences (from chimeric antibodies). Separate scores were computed for the VH (A, C) and the VL (B, D) . The scores obtained for our anti-TIGIT (upper panels) and anti-TIM3 (lower panels) candidates are compared with the benchmark distributions.

    Article Snippet: Antibodies-containing HEK293 supernatants were diluted in PPI Terbium Detection buffer and the binding to TIM3 (6-His C-ter-tagged, Acro Biosystems) or TIGIT (TIT-H52H5 Human TIGIT Protein, His Tag, active dimer, AcroBiosystems) diluted at 0.6 ng/µl final concentration in small volume 384-wells plates (Greiner Bio-One).

    Techniques:

    Off-targets prediction. The numbers of predicted off-targets, either human (red) or non-human (blue), were computed for all FDA-approved antibodies and ranked as a probability of being recognized (high vs. medium). The number of off-targets predicted for our anti-TIGIT (left panel) and anti-TIM3 (right panel) candidates were compared with that scale.

    Journal: Frontiers in Immunology

    Article Title: AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies

    doi: 10.3389/fimmu.2025.1499810

    Figure Lengend Snippet: Off-targets prediction. The numbers of predicted off-targets, either human (red) or non-human (blue), were computed for all FDA-approved antibodies and ranked as a probability of being recognized (high vs. medium). The number of off-targets predicted for our anti-TIGIT (left panel) and anti-TIM3 (right panel) candidates were compared with that scale.

    Article Snippet: Antibodies-containing HEK293 supernatants were diluted in PPI Terbium Detection buffer and the binding to TIM3 (6-His C-ter-tagged, Acro Biosystems) or TIGIT (TIT-H52H5 Human TIGIT Protein, His Tag, active dimer, AcroBiosystems) diluted at 0.6 ng/µl final concentration in small volume 384-wells plates (Greiner Bio-One).

    Techniques:

    Affinity evaluation and structural model definition of the antibody-antigen complexes. (A, B) Experimental competition assays. Pairwise competition assays of TIGIT binders (A) or anti-TIM3 antibodies (B) were performed by flow cytometry. Briefly, the Fc fragments of our human IgG1 candidates were replaced by mouse IgG2a Fc fragments. HEK293 cells were transiently transfected with the Flag-tagged target gene and co-incubated the human IgG1-formatted and the mouse IgG2a-formatted candidates. In the case of TIGIT, the competition was also evaluated with its natural ligand CD155 fused to a mouse IgG2a Fc fragment. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the human IgG1-formatted antibodies was followed with an APC-coupled antibody. The percentage of APC+PE+ cells (among the PE+ subset) was indicated as a color gradient. (C) Affinity predictions and structural model definition. The antibodies were docked on selected epitopes (indicated in the left boxes). The affinity of the obtained complexes was computed as the C-score (left column) which was a combination of PCC-score (middle column) and IR-score (right column). The upper panels show the affinity predicted for the anti-TIGIT candidates docked on 7VYT epitope. The middle and lower panels show the affinity predicted for the anti-TIM3 antibodies docked on 6TXZ and 7KQL epitope, respectively.

    Journal: Frontiers in Immunology

    Article Title: AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies

    doi: 10.3389/fimmu.2025.1499810

    Figure Lengend Snippet: Affinity evaluation and structural model definition of the antibody-antigen complexes. (A, B) Experimental competition assays. Pairwise competition assays of TIGIT binders (A) or anti-TIM3 antibodies (B) were performed by flow cytometry. Briefly, the Fc fragments of our human IgG1 candidates were replaced by mouse IgG2a Fc fragments. HEK293 cells were transiently transfected with the Flag-tagged target gene and co-incubated the human IgG1-formatted and the mouse IgG2a-formatted candidates. In the case of TIGIT, the competition was also evaluated with its natural ligand CD155 fused to a mouse IgG2a Fc fragment. The target expression was monitored with a PE-coupled anti-Flag antibody and the binding of the human IgG1-formatted antibodies was followed with an APC-coupled antibody. The percentage of APC+PE+ cells (among the PE+ subset) was indicated as a color gradient. (C) Affinity predictions and structural model definition. The antibodies were docked on selected epitopes (indicated in the left boxes). The affinity of the obtained complexes was computed as the C-score (left column) which was a combination of PCC-score (middle column) and IR-score (right column). The upper panels show the affinity predicted for the anti-TIGIT candidates docked on 7VYT epitope. The middle and lower panels show the affinity predicted for the anti-TIM3 antibodies docked on 6TXZ and 7KQL epitope, respectively.

    Article Snippet: Antibodies-containing HEK293 supernatants were diluted in PPI Terbium Detection buffer and the binding to TIM3 (6-His C-ter-tagged, Acro Biosystems) or TIGIT (TIT-H52H5 Human TIGIT Protein, His Tag, active dimer, AcroBiosystems) diluted at 0.6 ng/µl final concentration in small volume 384-wells plates (Greiner Bio-One).

    Techniques: Flow Cytometry, Transfection, Incubation, Expressing, Binding Assay